159 related articles for article (PubMed ID: 30248303)
1. Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
Brandt C; Seja P; Töllner K; Römermann K; Hampel P; Kalesse M; Kipper A; Feit PW; Lykke K; Toft-Bertelsen TL; Paavilainen P; Spoljaric I; Puskarjov M; MacAulay N; Kaila K; Löscher W
Neuropharmacology; 2018 Dec; 143():186-204. PubMed ID: 30248303
[TBL] [Abstract][Full Text] [Related]
2. A combination of phenobarbital and the bumetanide derivative bumepamine prevents neonatal seizures and subsequent hippocampal neurodegeneration in a rat model of birth asphyxia.
Johne M; Käufer C; Römermann K; Gailus B; Gericke B; Löscher W
Epilepsia; 2021 Jun; 62(6):1460-1471. PubMed ID: 33955541
[TBL] [Abstract][Full Text] [Related]
3. Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
Hampel P; Römermann K; Gailus B; Johne M; Gericke B; Kaczmarek E; Löscher W
Neuropharmacology; 2021 Mar; 185():108449. PubMed ID: 33450274
[TBL] [Abstract][Full Text] [Related]
4. The loop diuretic torasemide but not azosemide potentiates the anti-seizure and disease-modifying effects of midazolam in a rat model of birth asphyxia.
Welzel B; Schmidt R; Kirchhoff L; Gramer M; Löscher W
Epilepsy Behav; 2023 Feb; 139():109057. PubMed ID: 36586153
[TBL] [Abstract][Full Text] [Related]
5. CNS pharmacology of NKCC1 inhibitors.
Löscher W; Kaila K
Neuropharmacology; 2022 Mar; 205():108910. PubMed ID: 34883135
[TBL] [Abstract][Full Text] [Related]
6. Azosemide is more potent than bumetanide and various other loop diuretics to inhibit the sodium-potassium-chloride-cotransporter human variants hNKCC1A and hNKCC1B.
Hampel P; Römermann K; MacAulay N; Löscher W
Sci Rep; 2018 Jun; 8(1):9877. PubMed ID: 29959396
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of novel bumetanide derivatives for epilepsy treatment.
Auer T; Schreppel P; Erker T; Schwarzer C
Neuropharmacology; 2020 Jan; 162():107754. PubMed ID: 31476353
[TBL] [Abstract][Full Text] [Related]
8. The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain.
Hampel P; Römermann K; Gramer M; Löscher W
Epilepsy Behav; 2021 Jan; 114(Pt A):107616. PubMed ID: 33279441
[TBL] [Abstract][Full Text] [Related]
9. Bumetanide potentiates the anti-seizure and disease-modifying effects of midazolam in a noninvasive rat model of term birth asphyxia.
Welzel B; Johne M; Löscher W
Epilepsy Behav; 2023 May; 142():109189. PubMed ID: 37037061
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneous brain distribution of bumetanide following systemic administration in rats.
Löscher W; Gramer M; Römermann K
Biopharm Drug Dispos; 2024 Jun; 45(3):138-148. PubMed ID: 38823029
[TBL] [Abstract][Full Text] [Related]
11. Corrigendum to "Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's antiseizure efficacy" [Neuropharmacology 143 (2018) 186-204].
Brandt C; Seja P; Töllner K; Römermann K; Hampel P; Kalesse M; Kipper A; Feit PW; Lykke K; Toft-Bertelsen TL; Paavilainen P; Spoljaric I; Puskarjov M; MacAulay N; Kaila K; Löscher W
Neuropharmacology; 2018 Dec; 143():349-350. PubMed ID: 30343990
[No Abstract] [Full Text] [Related]
12. Astrocytic NKCC1 inhibits seizures by buffering Cl
Nguyen TD; Ishibashi M; Sinha AS; Watanabe M; Kato D; Horiuchi H; Wake H; Fukuda A
Epilepsia; 2023 Dec; 64(12):3389-3403. PubMed ID: 37779224
[TBL] [Abstract][Full Text] [Related]
13. Long-term alcohol exposure elicits hippocampal nonsynaptic epileptiform activity changes associated with expression and functional changes in NKCC1, KCC2 co-transporters and Na
Santos LEC; Rodrigues AM; Lopes MR; Costa VDC; Scorza CA; Scorza FA; Cavalheiro EA; Almeida AG
Neuroscience; 2017 Jan; 340():530-541. PubMed ID: 27871891
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Na
Zhang J; Pu H; Zhang H; Wei Z; Jiang X; Xu M; Zhang L; Zhang W; Liu J; Meng H; Stetler RA; Sun D; Chen J; Gao Y; Chen L
Neurochem Int; 2017 Dec; 111():23-31. PubMed ID: 28577991
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological tools to target NKCC1 in brain disorders.
Savardi A; Borgogno M; De Vivo M; Cancedda L
Trends Pharmacol Sci; 2021 Dec; 42(12):1009-1034. PubMed ID: 34620512
[TBL] [Abstract][Full Text] [Related]
16. Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective.
Johne M; Römermann K; Hampel P; Gailus B; Theilmann W; Ala-Kurikka T; Kaila K; Löscher W
Epilepsia; 2021 Apr; 62(4):920-934. PubMed ID: 33258158
[TBL] [Abstract][Full Text] [Related]
17. Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain.
Römermann K; Fedrowitz M; Hampel P; Kaczmarek E; Töllner K; Erker T; Sweet DH; Löscher W
Neuropharmacology; 2017 May; 117():182-194. PubMed ID: 28192112
[TBL] [Abstract][Full Text] [Related]
18. Effects of bumetanide on neonatal seizures: A systematic review of animal and human studies.
Rao S; Farhat A; Rakshasbhuvankar A; Athikarisamy S; Ghosh S; Nagarajan L
Seizure; 2023 Oct; 111():206-214. PubMed ID: 37690372
[TBL] [Abstract][Full Text] [Related]
19. A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy.
Gharaylou Z; Tafakhori A; Agah E; Aghamollaii V; Kebriaeezadeh A; Hadjighassem M
CNS Drugs; 2019 Mar; 33(3):283-291. PubMed ID: 30784026
[TBL] [Abstract][Full Text] [Related]
20. Impaired chloride homeostasis in epilepsy: Molecular basis, impact on treatment, and current treatment approaches.
Auer T; Schreppel P; Erker T; Schwarzer C
Pharmacol Ther; 2020 Jan; 205():107422. PubMed ID: 31626872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
